Dtsch Med Wochenschr 2011; 136(31/32): 1598-1600
DOI: 10.1055/s-0031-1281562
Rheumatologie | Commentary
Rheumatologie
© Georg Thieme Verlag KG Stuttgart · New York

Schmerztherapie bei rheumatologischen Erkrankungen

Treatment of pain in rheumatic diseasesF. Luttosch1 , C. Baerwald1
  • 1Sektion Rheumatologie, Department für Innere Medizin, Neurologie und Dermatologie, Universitätsklinikum Leipzig
Further Information

Publication History

Publication Date:
01 August 2011 (online)

Literatur

  • 1 Baerwald C, Verdecchia P, Duquesroix B. et al . Efficacy, safety, and effects on blood pressure of naproxcinod 750 mg twice daily compared with placebo and naproxen 500 mg twice daily in patients with osteoarthritis of the hip: a randomized, double-blind, parallel-group, multicenter study.  Arthritis Rheum. 2010;  62 3635-3644
  • 2 Becker G, Blum H. Novel opioid antagonists for opioid-induced bowel dysfunction and postoperative ileus.  Lancet. 2009;  373 1198-206
  • 3 Bolten W. Neubewertung der NSAR im dreistufigen WHO-Schmerztherapie-Schema.  Arthritis Rheuma. 2011;  31 89-98
  • 4 Chan F, Lanas A, Scheiman J. et al . Celecoxib versus omeprazole and diclofenac in patients with osteoarthritis and rheumatoid arthritis (CONDOR): a randomised trial.  Lancet. 2010;  376 173-179
  • 5 Hale M, Upmalis D, Okamoto A. et al . Tolerability of tapentadol immediate release in patients with lower back pain or osteoarthritis of the hip or knee over 90 days: a randomized, double-blind study.  Curr Med Res Opin. 2009;  25 1095-1104
  • 6 Karlsson J, Pivodic A, Aguirre D. et al . Efficacy, safety, and tolerability of the cyclooxygenase-inhibiting nitric oxide donator naproxcinod in treating osteoarthritis of the hip or knee.  J Rheumatol. 2009;  36 1290-1297
  • 7 Laine L, Curtis S, Cryer B. et al . Risk factors for NSAID-associated upper GI clinical events in a long-term prospective study of 34,701 arthritis patients.  Aliment Pharmacol Ther. 2010;  32 1240-1248
  • 8 Lane N, Schnitzer T, Birbara C. et al . Tanezumab for the treatment of pain from osteoarthritis of the knee.  N Engl J Med. 2010;  363 1521-1531
  • 9 McDougall J. Arthritis and pain. Neurogenic origin of joint pain.  Arthritis Res Ther. 2006;  8 220
  • 10 Trelle S, Reichenbach S, Wandel S. et al . Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis.  Brit Med J. 2011;  342 c7086
  • 11 Van der Linden M, Gaugris S, Kuipers E. et al . COX-2 inhibitors: complex association with lower risk of hospitalization for gastrointestinal events compared to traditional NSAIDs plus proton pump inhibitors.  Pharmacoepidemiol Drug Saf. 2009;  18 880-890
  • 12 Vauth C, Greiner W. Kosten in der Schmerztherapie.  Gesundh ökon Qual manag. 2011;  16 S3-S9

Dr. Franziska Luttosch

Sektion Rheumatologie/Gerontologie
Department für Innere Medizin, Neurologie und Dermatologie
Universitätsklinikum Leipzig

Liebigstr. 20

04103 Leipzig

Phone: 0341/9724710

Fax: 0341/9724709

Email: franziska.luttosch@medizin.uni-leipzig.de